The FDA made an about-face one day after posting revised briefing documents for Monday's Peripheral and Central Nervous System Drugs (PCNS) Advisory Committee meeting to discuss the new drug application (NDA) for the Duchenne muscular dystrophy (DMD) candidate, eteplirsen, from Sarepta Therapeutics Inc., of Cambridge, Mass.